Skip to main content
OpenTrials
Completed

NCT Number: NCT01594762

Pexiganan Versus Placebo Control for the Treatment of Mild Infections of Diabetic Foot Ulcers

The purpose of this study is to establish the clinical superiority and the safety of topical pexiganan cream 0.8% plus standard local wound care as compared to placebo cream plus standard local wound care, in the treatment of mildly infected diabetic foot ulcers.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Phoenix, Arizona, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Diabetes mellitus.
  • Male or female at least 18 years old.
  • Subject must agree to adhere to all protocol procedures and return for all scheduled visits, and must be willing and able to provide written informed consent.
  • Subject is to be treated on an outpatient basis.
  • Full thickness ulcer or a partial thickness ulcer on the foot distal to the malleoli with a surface area ≥ 1 cm2 after the wound has undergone appropriate debridement.
  • Localized mild infection of the ulcer.
  • The diagnosis of mild infection must be confirmed immediately following debridement at Baseline.
  • Subject must have plain radiographs taken within 2 days prior to entry showing no evidence of bony abnormalities consistent with osteomyelitis, or gas compatible with tissue crepitus, in the affected foot.

Exclusion criteria

  • IDSA-defined moderate infection, including cellulitis extending > 2 cm; lymphangitis; spread beneath the fascia; deep tissue abscess; gangrene; muscle, joint, or bone involvement.
  • IDSA-defined severe infection, including systemic toxicity or metabolic instability.
  • Infected diabetic foot ulcer that is associated with local wound complications such as prosthetic materials or protruding surgical hardware.
  • > 1 infected foot ulcer.
  • Subject is currently receiving topical antimicrobial treatment for a localized infection of the study ulcer and whose infection is improving in response to treatment.
  • Subject has received a systemic antibiotic within 48 hours prior to Screening.
  • Concurrent or expected to require systemic antimicrobials during the study period for any infection, including diabetic foot ulcer.
  • Bone or joint involvement is suspected based on clinical examination or plain X-ray.
  • Clinically significant peripheral arterial disease requiring vascular intervention.
  • Subject is expected to be unable to care for the ulcer or return for all scheduled visits because of hospitalization, vacation, disability, etc. during the study period, or is unable to safely monitor the infection status at home.

Treatment and study plan

Topical pexiganan cream 0.8%

Drug

14 days of treatment

Other names: MSI-78

Topical placebo cream

Drug

14 days of treatment

Standard Wound Care

Other

14 days of treatment

Primary outcomes

  1. Number of Participants With Clinical Response

    Time frame: 28 days

    The numbers of participants with Clinical Response, defined as resolution of infection, are reported.

Secondary outcomes

  1. Number of Participants With Microbiological Response

    Time frame: 28 days

    The numbers of participants with Microbiological Response, defined are eradication of all baseline pathogens, are reported.

  2. Number of Participants With Treatment-Emergent Adverse Events (TEAE)

    Time frame: 28 days

    The number of participants with TEAEs, including Serious TEAEs, are reported

Sponsors and collaborators

Lead sponsor

Dipexium Pharmaceuticals, Inc.

Industry

Registry information

Official study title

A Randomized, Double-Blind, Multicenter, Superiority, Placebo-Controlled Phase 3 Study of Pexiganan Cream 0.8% Applied Twice Daily for 14 Days in the Treatment of Adults With Mild Infections of Diabetic Foot Ulcers

Acronym: OneStep-2

Important dates

Study start
2014
Primary completion
2016
Study completion
2016
First posted
May 9, 2012
Registry last updated
Jun 14, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.